MiR-182-5p promotes proliferation and invasion by regulating Smad4 in vulvar squamous cell cancer

The purpose of this study was to investigate the potential mechanism of miR-182-5p and Smad4 in vulvar squamous cell carcinoma (VSCC). A431 cells were transfected with miR-182-5p mimics, a small interfering RNA targeting Smad4 (siR-Smad4) and their negative controls. The authors performed gene functional experiments in A431 cells. The protein levels of MMP-2, MMP-9, E-cadherin, N-cadherin, and vimentin were detected after transfection miR-182-5p mimics. The expression levels of Smad4, p21, plasminogen activator inhibitor-1 (PAI-1), Bax, and Bim were detected after transfection miR-182-5p mimics. In A431 cells, up-expression of miR-182- 5p advanced the cell proliferation, migration, invasion, G1-S phase transition, and down-regulated Smad4; miR-182-5p also increased the expressions of MMP-2 and MMP-9 and influenced alterations in epithelial-mesenchymal transition (EMT) and suppressed downstream target genes of Smad4. The down-regulation of Smad4 by siRNA simulated the roles of miR-182-5p. The authors conclude that miR-182-5p plays an oncogenic role by its target gene Smad4 in VSCC.

Vulvar squamous cell carcinoma; miR-182-5p; Smad4; Epithelial-mesenchymal transition.

[1] Barlow E.L., Kang Y.J., Hacker N.F.: “Changing trends in vulvar cancer incidence and mortality rates in Australia since 1982”. Int. J. Gynecol. Cancer, 2015, 25, 1683.

[2] Yang X.H., Wu X.: “miRNA expression profile of vulvar squamous cell carcinoma and identification of the oncogenic role of miR-182- 5p”. Oncol. Rep., 2016, 35, 398.

[3] Hirata H., Ueno K., Shahryari V., Tanaka Y., Tabatabai Z.L., Hinoda Y., et al.: “Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer”. PLoS One, 2012, 7, e51056.

[4] de Melo Maia B., Lavorato-Rocha A.M., Rodrigues L.S., Coutinho- Camillo C.M., Baiocchi G., Stiepcich M.M., et al.: “microRNA portraits in human vulvar carcinoma”. Cancer Prev, Res, (Phila,), 2013, 6, 1231.

[5] de Melo Maia B., Ling H., Monroig P., Ciccone M., Soares F.A., Calin G.A., et al.: “Design of a miRNA sponge for the miR- 17 miRNA family as a therapeutic strategy against vulvar carcinoma”. Mol. Cell Probes, 2015, 29, 420.

[6] Chiang C.H., Hou M.F., Hung W.C.: “Up-regulation of miR-182 by betacatenin in breast cancer increases tumourigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK”. Biochim. Biophys. Acta, 2013, 1830, 3067.

[7] Hirata H., Ueno K., Shahryari V., Deng G., Tanaka Y., Tabatabai Z.L., et al.: “MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer”. PLoS One, 2013, 8, e55502.

[8] Wang J., Li J., Shen J., Wang C., Yang L., Zhang X.: “MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma”. BMC Cancer, 2012, 12, 227.

[9] Tang T., Wong H.K., Gu W., Yu M.Y., To K.F., Wang C.C., et al.: “MicroRNA-182 plays an onco-miRNA role in cervical cancer”. Gynecol. Oncol., 2013, 129, 199.

[10] Cekaite L., Rantala J.K., Bruun J., Guriby M., Agesen T.H., Danielsen S.A., et al.: “MiR-9, -31, and -182 deregulation promote proliferation and tumour cell survival in colon cancer”. Neoplasia, 2012, 14, 868.

[11] Song L., Liu L., Wu Z., Li Y., Ying Z., Lin C., et al.: “TGF-beta induces miR-182 to sustain NF-kB activation in glioma subsets”. J. Clin. Invest., 2012, 122, 3563.

[12] Wang L., Zhu M.J., Ren A.M., Wu H.F., Han W.M., Tan R.Y., et al.: “A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer”. PLoS One, 2014, 9, e96472.

[13] Yan D., Dong X.D., Chen X., Yao S., Wang L., Wang J., et al.: “Role of microRNA-182 in posterior uveal melanoma: regulation of tumour development through MITF, BCL2 and cyclin D2”. PLoS One, 2012, 7, e40967.

[14] Xu X., Wu J., Li S., Hu Z., Xu X., Zhu Y., et al.: “Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway”. Mol. Cancer, 2014, 13, 109.

[15] Kong W.Q., Bai R., Liu T., Cai C.L., Liu M., Li X., et al.: “MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma”. FEBS J., 2012, 279, 1252.

[16] Zanvettor PH, Filho DF, Soares FA, Neves AR, Palmeira LO.: “Study of biomolecular and clinical prognostic factors in patients with cancer of the vulva undergoing surgical treatment”. Int. J. Gynecol. Cancer, 2014, 24, 766.

[17] Chen Y., Xiao Y., Ge W., Zhou K., Wen J., Yan W., et al.: “MiR-200b inhibits TGF-beta1-induced epithelial–mesenchymal transition and promotes growth of intestinal epithelial cells”. Cell Death Dis., 2013, 4, e541.

[18] Paterson E.L., Kazenwadel J., Bert A.G., Khew-Goodall Y., Ruszkiewicz A., Goodall G.J.: “Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression”. Neoplasia, 2013, 15, 180.

[19] Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., et al.: “A microRNA targeting dicer for metastasis control”. Cell, 2010, 141, 1195.

[20] Hunt K.K., Fleming J.B., Abramian A., Zhang L., Evans D.B., Chiao P.J.: “Overexpression of the tumour suppressor gene Smad4/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells”. Cancer Res., 1998, 5, 5656.

[21] Boye A., Wu C., Jiang Y., Wang J., Wu J., Yang X., et al.: “Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPKregulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism”. J. Ethnopharmacol., 2015, 169, 219.

[22] Janeesh P.A., Abraham.: “Robinin modulates doxorubicin-induced cardiac apoptosis by TGF-β1 signaling pathway in Sprague Dawley rats”. Biomed. Pharmacother., 2014, 68, 989.

[23] Tong D., Qu H., Meng X., Jiang Y., Liu D., Ye S., et al.: “S-allylmercaptocysteine promotes MAPK inhibitor-induced apoptosis by activating the TGF-β signaling pathway in cancer cells”. Oncology Reports, 2014, 32, 1124.

[24] Freeman T.J., Smith J.J., Chen X., Washington M.K., Roland J.T., Means A.L., et al.: “Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin”. Gastroenterology, 2012, 142, 562.

[25] Yang G., Yang X.: “Smad4-mediated TGF-β signaling in tumourigenesis”. Int. J. Biol. Sci., 2010, 6, 1.

[26] Cheng H., Fertig E.J., Ozawa H., Hatakeyama H., Howard J.D., Perez J., et al.: “Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma”. Cancer Biol. Ther., 2015, 16, 1252.

[27] Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., et al.: “DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1”. Science. 1996, 271, 350.

[28] Cancer Genome Atlas Network: “Comprehensive genomic characterization of head and neck squamous cell carcinomas”. Nature, 2015, 517, 576.

[29] Liu Y., Sheng J., Dai D., Liu T., Qi F.: “Smad4 acts as tumour suppressor by antagonizing lymphangiogenesis in colorectal cancer”. Pathol. Res. Pract., 2015, 211, 286.

[30] Cho S.Y., Ha S.Y., Huang S.M., Kim J.H., Kang M.S., Yoo H.Y., et al.: “The prognostic significance of Smad3, Smad4, Smad3 phosphoisoform expression in esophageal squamous cell carcinoma”. Med. Oncol., 2014, 31, 236.

[31] Bian C., Li Z., Xu Y., Wang J., Xu L., Shen H.: “Clinical outcome and expression of mu-tant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study”. World J. Surg. Oncol., 2015, 13, 128.

[32] Liu N.N., Xi Y., Callaghan M.U., Fribley A., Moore-Smith L., Zimmerman J.W., et al.: “SMAD4 is a potential prognostic marker in human breast carcinomas”. Tumour Biol., 2014, 35, 641.